drugset / Trial / NCT01842074
Desensitization With Bortezomib Before a Living Kidney Donation
NaSingle-groupOpen-labelTreatment
Summary
The investigators plan to study the role of bortezomib for desensitizing patients awaiting a living kidney donation who have a titer of Donor Specific anti human leucocyte antigen (HLA) Antibody (DSA) between 1000 and 3000 MFI with a pilot study of 10 patients recruited in 4 hospital in FRANCE.
Timeline
- Start
- 2013-03
- Primary completion
- 2017-03
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
Indications
No indication recorded.